JPS60163811A - プロプラノロ−ル含有外用貼付剤 - Google Patents
プロプラノロ−ル含有外用貼付剤Info
- Publication number
- JPS60163811A JPS60163811A JP59018377A JP1837784A JPS60163811A JP S60163811 A JPS60163811 A JP S60163811A JP 59018377 A JP59018377 A JP 59018377A JP 1837784 A JP1837784 A JP 1837784A JP S60163811 A JPS60163811 A JP S60163811A
- Authority
- JP
- Japan
- Prior art keywords
- propranolol
- water
- administration
- plaster
- paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960003712 propranolol Drugs 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 5
- 239000002985 plastic film Substances 0.000 claims abstract description 5
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229920003169 water-soluble polymer Polymers 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000011505 plaster Substances 0.000 abstract description 7
- 238000010186 staining Methods 0.000 abstract description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 abstract description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract description 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 208000010201 Exanthema Diseases 0.000 abstract description 2
- 206010003119 arrhythmia Diseases 0.000 abstract description 2
- 230000006793 arrhythmia Effects 0.000 abstract description 2
- 201000005884 exanthem Diseases 0.000 abstract description 2
- 206010037844 rash Diseases 0.000 abstract description 2
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- 239000011369 resultant mixture Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- -1 glycerin fatty acid ester Chemical class 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59018377A JPS60163811A (ja) | 1984-02-06 | 1984-02-06 | プロプラノロ−ル含有外用貼付剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59018377A JPS60163811A (ja) | 1984-02-06 | 1984-02-06 | プロプラノロ−ル含有外用貼付剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60163811A true JPS60163811A (ja) | 1985-08-26 |
| JPH0367042B2 JPH0367042B2 (enrdf_load_stackoverflow) | 1991-10-21 |
Family
ID=11970021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59018377A Granted JPS60163811A (ja) | 1984-02-06 | 1984-02-06 | プロプラノロ−ル含有外用貼付剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60163811A (enrdf_load_stackoverflow) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63104913A (ja) * | 1986-10-21 | 1988-05-10 | Teikoku Seiyaku Kk | 外用貼付剤 |
| JPS63238017A (ja) * | 1987-03-26 | 1988-10-04 | Teikoku Seiyaku Kk | 塩酸カルテオロ−ルを含有する水性外用貼付剤 |
| EP1084716A3 (de) * | 1999-06-04 | 2002-04-24 | LTS Lohmann Therapie-Systeme AG | Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung |
| WO2015093503A1 (ja) * | 2013-12-18 | 2015-06-25 | 丸石製薬株式会社 | 含水型貼付剤 |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
-
1984
- 1984-02-06 JP JP59018377A patent/JPS60163811A/ja active Granted
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63104913A (ja) * | 1986-10-21 | 1988-05-10 | Teikoku Seiyaku Kk | 外用貼付剤 |
| JPS63238017A (ja) * | 1987-03-26 | 1988-10-04 | Teikoku Seiyaku Kk | 塩酸カルテオロ−ルを含有する水性外用貼付剤 |
| EP1084716A3 (de) * | 1999-06-04 | 2002-04-24 | LTS Lohmann Therapie-Systeme AG | Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
| WO2015093503A1 (ja) * | 2013-12-18 | 2015-06-25 | 丸石製薬株式会社 | 含水型貼付剤 |
| JPWO2015093503A1 (ja) * | 2013-12-18 | 2017-03-23 | 丸石製薬株式会社 | 含水型貼付剤 |
| US9974754B2 (en) | 2013-12-18 | 2018-05-22 | Maruishi Pharmaceutical Co., Ltd. | Hydrous adhesive patch |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0367042B2 (enrdf_load_stackoverflow) | 1991-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chien | Development of transdermal drug delivery systems | |
| KR0143916B1 (ko) | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 | |
| KR960001373B1 (ko) | 제약학적 활성 물질의 침투 증강용 2성분계 침투증강 조성물 | |
| EP0698393A1 (en) | Solubilizing agent and external preparation containing the same | |
| US20030072814A1 (en) | Topical pharmaceutical composition for the treatment of warts | |
| PT871420E (pt) | Triacetina como um estimulador de penetracao transdermica | |
| JP2003532629A (ja) | 第４アンモニウム塩の経皮薬剤放出への使用 | |
| NZ228826A (en) | Transdermal adhesive medicament containing eucalyptol (1,8 cineol) | |
| KR890000183B1 (ko) | 경피 침투가 증진된 생리학적 활성 제제 및 그의 제조방법 | |
| EP0947584A1 (en) | Loxoprofen-containing preparation for external use | |
| US11826478B2 (en) | Transdermal delivery formulation | |
| JPH06507888A (ja) | 経皮投与用メデトミジン製剤 | |
| KR950006217B1 (ko) | 니코란딜 외용제 | |
| JP2008534474A (ja) | 経皮パッチ | |
| SK126093A3 (en) | Lanoline derivatives as a penetration-promoting substances | |
| JPS60163811A (ja) | プロプラノロ−ル含有外用貼付剤 | |
| EP0491076A1 (en) | Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols | |
| JPS61268631A (ja) | 経皮吸収性を高めた皮膚外用剤 | |
| HU205722B (en) | Method for producing self-adhesive device serving for percutaneous feeding agent | |
| CA2038969A1 (en) | Compositions comprising cytotoxic agent and permeation enhancers | |
| JPS61268632A (ja) | 経皮吸収性を高めた皮膚外用剤 | |
| WO2005046654A1 (en) | Antiphlogistic and analgesic plaster comprising piroxicam compound | |
| JPH0567127B2 (enrdf_load_stackoverflow) | ||
| JPH03148218A (ja) | コルヒチン含有外用剤 | |
| EP1043979B1 (en) | Compositions for the transdermal and dermal administration of biologically active agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |